Amesite secures new sales win targeting post-acute care organizations
What happened
Amesite announced a new sales win utilizing its minimum enterprise pricing model for post-acute care organizations. Under this model, the NurseMagic® Enterprise platform is priced at $1,099 per month for organizations with up to 1,000 patients under a 12-month contract. The company estimates that agreements at this level generate approximately 85% gross margin.
From manilatimes.net
Why it matters
The pricing model provides commercial validation for serving smaller post-acute care organizations while supporting scalable revenue growth. This follows previous announcements of 63% revenue growth from NurseMagic® Enterprise.
Roadzen and Amesite are newly listed on the Nasdaq stock exchange, and Roadzen operates as an insurance-as-a-service platform in the United States.
From manilatimes.net
Who's involved
- NasdaqThe stock exchange where Amesite is listed
Keep exploring
The entities involved
-
Nasdaq
American fully electronic stock exchange
Related events
- Korro Bio, Inc. and Wellgistics Health were listed on the Nasdaq stock exchange on July 1, 2026.
- Iovance Biotherapeutics listed its stock on Nasdaq and received Fast Track designation from the FDA.
- Incannex Healthcare Inc. stock was traded on the Nasdaq exchange on June 29, 2026.
- Royal Bank of Canada increased its stock holdings in Option Care Health, Inc., which trades on the Nasdaq exchange, and the company filed disclosures with the SEC.
- BrightSpring Health Services stock is trading on the Nasdaq exchange.